PROFUNDS's PROFUND VP BIOTECHNOLOGY has disclosed 123 total holdings in their latest N-PORT filing with the SEC for the
portfolio date of 2025-03-31. The current portfolio value is calculated to be $29.00 Mil, only including common equities, preferred
equities, ETFs, options and warrants for equities. The turnover rate is 5%.
PROFUND VP BIOTECHNOLOGY's
Total Assets is $30.98 Mil , Total Liabilities is $1.15 Mil , Net Assets is $29.83 Mil.
In PROFUND VP BIOTECHNOLOGY's current portfolio as of 2025-03-31, the top 5 holdings are
Alnylam Pharmaceuticals Inc (ALNY), Insmed Inc (INSM), Neurocrine Biosciences Inc (NBIX), United Therapeutics Corp (UTHR) and Amgen Inc (AMGN),
not including call and put options.
PROFUND VP BIOTECHNOLOGY did not buy any new stocks in the current portfolio.
Please visit the "Current Portfolio" tab to see the mutual fund's current and past N-PORT holdings for PROFUND VP BIOTECHNOLOGY, as well as holding map,
valuations for each stock, which positions are undervalued, have low PE Ratios, are considered high quality and recently traded at 52-week lows, etc.
Please visit the "Stock Picks" tab to see the mutual fund's latest trades and stock picks for PROFUND VP BIOTECHNOLOGY, which include data from form N-PORT.
Please visit the "Summary" page to see the top 10 holdings, recent stock picks, performance, sector / industry breakdown details, as well as past holding history summary for PROFUND VP BIOTECHNOLOGY.